{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"DeLLphi-309","nct_id":"NCT06745323","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-309-nct06745323. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"DeLLphi-309","arms":[{"description":"Participants will receive dose 1 of Tarlatamab by intravenous (IV) infusion during the treatment period.","label":"Treatment Arm A: Dose 1 Tarlatamab","type":"EXPERIMENTAL"},{"description":"Participants will receive dose 2 of Tarlatamab by IV infusion during the treatment period.","label":"Treatment Arm B: Dose 2 Tarlatamab","type":"EXPERIMENTAL"},{"description":"Participants will receive dose 3 of Tarlatamab by IV infusion during the treatment period.","label":"Treatment Arm C: Dose 3 Tarlatamab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-08-10","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer (SCLC)"],"enrollment":{"count":252,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tarlatamab","type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Amgen","official_title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-08-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Proportion of participants with confirmed objective response to Tarlatamab","timeFrame":"Approximately 52 Months"},{"measure":"Proportion of participants with complete response to Tarlatamab","timeFrame":"Approximately 52 Months"},{"measure":"Proportion of participants with partial response to Tarlatamab","timeFrame":"Approximately 52 Months"}],"references":[],"start_date":{"date":"2025-02-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","url":"https://clinicaltrials.gov/study/NCT06745323"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-309-nct06745323"}